Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility

MARINA DEL REY, Calif., Nov. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company has entered into a new lease to build a 56,300 square-foot research and development and GMP manufacturing facility in Los Angeles.

"Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata. "In addition to our Phase 1b/2a clinical trial of AP-PA02 that is currently progressing, we are preparing to enter a second candidate, AP-SA02, into the clinic next year, and we are making meaningful progress toward advancing a third candidate into clinical development."

"In addition, we believe this new, state-of-the-art facility is essential for our novel product form given the scarcity of phage-specific manufacturing capacity. Building out multiple manufacturing lines also positions us to evaluate potential strategic partnerships and collaborations that, if consummated, can further expand our pipeline, accelerate clinical development, and offer opportunities for long-term value creation."

READ FULL ARTICLE HERE